(Q36373318)

13 August 2017

1 reference

title

Lupus in Baltimore: evidence-based 'clinical pearls' from the Hopkins Lupus Cohort (English)

1 reference

13 August 2017

1

M Petri

1 reference

13 August 2017

language of work or name

1 reference

1 January 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

14

1 reference

13 August 2017

issue

12

1 reference

13 August 2017

page(s)

970-973

1 reference

Morbidity of systemic lupus erythematosus: role of race and socioeconomic status

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2230XX

Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2230XX

The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2230XX

Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2230XX

Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus--a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2230XX

The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2230XX

A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2230XX

Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2230XX

Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2230XX

The Hopkins Lupus Pregnancy Center: 1987–1991 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2230XX

The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2230XX

Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2230XX

Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2230XX

10.1191/0961203305LU2230XX

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference